Tangen C - Search Results

1

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).

Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Goldkorn A, et al. Among authors: tangen c. Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26. Clin Cancer Res. 2021. PMID: 33500355 Free PMC article. Clinical Trial.

2

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Thompson IM, Tangen C, Basler J, Crawford ED. Thompson IM, et al. Among authors: tangen c. J Urol. 2002 Sep;168(3):1008-12. doi: 10.1016/S0022-5347(05)64562-4. J Urol. 2002. PMID: 12187210 Clinical Trial.

3

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.

Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. Klein CE, et al. Prostate. 2002 Sep 1;52(4):264-8. doi: 10.1002/pros.10118. Prostate. 2002. PMID: 12210486 Clinical Trial.

4

Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

Glass TR, Tangen CM, Crawford ED, Thompson I. Glass TR, et al. J Urol. 2003 Jan;169(1):164-9. doi: 10.1016/S0022-5347(05)64059-1. J Urol. 2003. PMID: 12478127 Clinical Trial.

5

The Prostate Cancer Prevention Trial: design, status, and promise.

Thompson IM, Tangen C, Goodman P. Thompson IM, et al. Among authors: tangen c. World J Urol. 2003 May;21(1):28-30. doi: 10.1007/s00345-002-0315-y. Epub 2003 Feb 14. World J Urol. 2003. PMID: 12756491 Review.

6

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. Thompson IM, et al. N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24. N Engl J Med. 2003. PMID: 12824459 Free article. Clinical Trial.

7

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Grossman HB, et al. N Engl J Med. 2003 Aug 28;349(9):859-66. doi: 10.1056/NEJMoa022148. N Engl J Med. 2003. PMID: 12944571 Free article. Clinical Trial.

8

Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.

Tangen CM, Goodman PJ, Crowley JJ, Thompson IM. Tangen CM, et al. J Urol. 2004 Feb;171(2 Pt 2):S64-7. doi: 10.1097/01.ju.0000108260.33590.c8. J Urol. 2004. PMID: 14713757

9

Ten-year survival in patients with metastatic prostate cancer.

Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Tangen CM, et al. Clin Prostate Cancer. 2003 Jun;2(1):41-5. doi: 10.3816/cgc.2003.n.011. Clin Prostate Cancer. 2003. PMID: 15046683 Clinical Trial.

10

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Thompson IM, et al. N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918. N Engl J Med. 2004. PMID: 15163773 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters